Stockreport

Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries

Medigus Ltd. - American Depositary Shares  (MDGS) 
US:NASDAQ Investor Relations: medigus.com/investor-relations/investor-faqs
PDF Polyrizon will be entitled for up to $3.35 million in addition to future royalties Tel Aviv, Israel, July 18, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), [Read more]